Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action

Novel strategies are proposed to quantitatively analyze and relate biological pathways to drug responses using gene expression and small-molecule growth inhibition data (GI50) derived from the National Cancer Institute's 60 cancer cells (NCI60). We have annotated groups of drug GI50 responses with pathways defined by the Kyoto Encyclopedia of Genes and Genomes (KEGG) and BioCarta, and functional categories defined by Gene Ontology (GO), through correlations between pathway gene expression patterns and drug GI50 profiles. Drug–gene-pathway relationships may then be utilized to find drug targets or target-specific drugs. Significantly correlated pathways and the gene products involved represent interesting targets for further exploration, whereas drugs that are significantly correlated with only certain pathways are more likely to be target specific. Separate pathway clustering finds that pathways engaged in the same biological process tend to have similar drug correlation patterns. The biological and statistical significances of our method are established by comparison to known small-molecule inhibitor–gene target relationships reported in the literature and by standard randomization procedures. The results of our pathway, gene expression and drug-induced growth inhibition associations, can serve as a basis for proposing testable hypotheses about potential anticancer drugs, their targets, and mechanisms of action.

[1]  [Receiver operating curve, an aid in decision making. Principles and applications illustrated with some examples]. , 1988, Journal de gynecologie, obstetrique et biologie de la reproduction.

[2]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[3]  Teuvo Kohonen,et al.  Self-Organizing Maps , 2010 .

[4]  M. Grever,et al.  Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. , 1995, The Journal of clinical investigation.

[5]  J N Weinstein,et al.  Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. , 1997, Journal of the National Cancer Institute.

[6]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[7]  Edward A. Sausville,et al.  Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines , 1997, Nature Medicine.

[8]  Milan Randic,et al.  On Characterization of Chemical Structure , 1997, J. Chem. Inf. Comput. Sci..

[9]  A. Butte,et al.  Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[11]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[12]  John N. Weinstein,et al.  Analysis of gene expression data of the NCl 60 cancer cell lines using Bayesian hierarchical effects model , 2001, SPIE BiOS.

[13]  J. Weinstein,et al.  Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data , 2002, The Pharmacogenomics Journal.

[14]  William C Reinhold,et al.  Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. , 2002, Cancer research.

[15]  E. Sausville,et al.  Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. , 2002, Journal of medicinal chemistry.

[16]  In vitro antitumor structure-activity relationships of threo/trans/threo/trans/erythro bis-tetrahydrofuranic acetogenins: correlations with their inhibition of mitochondrial complex I. , 2003 .

[17]  Alan Ruttenberg,et al.  Computational knowledge integration in biopharmaceutical research , 2003, Briefings Bioinform..

[18]  In vitro antitumor structure-activity relationships of threo/trans/threo mono-tetrahydrofuranic acetogenins: correlations with their inhibition of mitochondrial complex I. , 2003, Oncology research.

[19]  P Champy,et al.  The mitochondrial complex i inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism , 2003, Neuroscience.

[20]  Anders Wallqvist,et al.  Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data , 2003, Bioinform..

[21]  A. Bermejo,et al.  Inhibitory effects on mitochondrial complex I of semisynthetic mono-tetrahydrofuran acetogenin derivatives. , 2003, Bioorganic & medicinal chemistry letters.

[22]  K-C Li,et al.  A functional genomic study on NCI's anticancer drug screen , 2004, The Pharmacogenomics Journal.

[23]  Todd R Golub,et al.  Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation , 2004, Nature Genetics.

[24]  A. Westwell,et al.  Hitting the chemotherapy jackpot: strategy, productivity and chemistry. , 2004, Drug discovery today.

[25]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[26]  William C Reinhold,et al.  Membrane Transporters and Channels , 2004, Cancer Research.

[27]  A rational selection of drug targets needs deeper insights into general regulation mechanisms. , 2004, Current medicinal chemistry. Anti-cancer agents.

[28]  C. Barbacioru,et al.  Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1 , 2005, The Pharmacogenomics Journal.

[29]  Ruili Huang,et al.  Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small‐molecule screening and structural databases , 2005, Proteins.

[30]  Noriyuki Nakatsu,et al.  Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays , 2005, Molecular Cancer Therapeutics.

[31]  Ruili Huang,et al.  Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. , 2005, Biochemical pharmacology.

[32]  Ruili Huang,et al.  Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen. , 2006, Genomics.